OM1, formerly Better Outcomes, is a leading health outcomes and registries company focused on the measurement, comparison, and prediction of treatment outcomes.
OM1 helps customers generate and use real-world evidence more rapidly and effectively to gain regulatory approval, understand the effectiveness, safety and value of treatments, and personalize care.
OM1 was founded in 2015 by Dr. Richard Gliklich. The company is headquartered in Boston, Massachusetts.
OM1 focuses on specific therapeutic areas, including chronic conditions like immunology, rheumatology, cardiometabolic disorders, musculoskeletal conditions and central nervous system (CNS)/behavioral health.
OM1 leverages big data, standardized outcomes measurement, and artificial intelligence technology, to build the first intelligent data cloud for healthcare, enabling more precise information and better decision making for stakeholders across the healthcare ecosystem.
OM1's products include, in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and state-of-the art AI solutions for measuring and predicting outcomes for patients and populations.
OM1 is backed by Scale Venture Partners, General Catalyst (GC), Polaris Partners, 7wire Ventures and others. The company raised $50M in a Series C financing on Dec 18, 2019. This new round brings OM1's total funding to $86M to date.